MEDICAL ASSISTANCE
BULLETIN

ISSUE DATE
September 10, 2019

EFFECTIVE DATE
January 1, 2020

NUMBER
*See below

SUBJECT
Prior Authorization of Ophthalmics, Anti-Inflammatories – Pharmacy Services

BY
Sally A. Kozak, Deputy Secretary
Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at:

PURPOSE:

The purpose of this bulletin is to issue updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Ophthalmics, Anti-Inflammatories submitted for prior authorization.

SCOPE:

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program and providing services in the Fee-for-Service delivery system. Providers rendering services in the MA managed care delivery system should address any questions related to Ophthalmics, Anti-Inflammatories to the appropriate managed care organization.

BACKGROUND:

The Department of Human Services’ (Department) Pharmacy and Therapeutics (P&T)

<table>
<thead>
<tr>
<th>*01-19-56</th>
<th>09-19-52</th>
<th>27-19-50</th>
</tr>
</thead>
<tbody>
<tr>
<td>02-19-50</td>
<td>11-19-49</td>
<td>30-19-48</td>
</tr>
<tr>
<td>03-19-49</td>
<td>14-19-48</td>
<td>31-19-55</td>
</tr>
</tbody>
</table>

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type

Visit the Office of Medical Assistance Programs Web site at
http://www.dhs.pa.gov/provider/healthcaremedicalassistance/index.htm
Committee reviews published peer-reviewed clinical literature and makes recommendations relating to the following:

- Preferred or non-preferred status for new drugs in therapeutic classes already included in the Preferred Drug List (PDL);
- Changes in the status of drugs on the PDL from preferred to non-preferred and non-preferred to preferred;
- New quantity limits;
- Classes of drugs to be added to or deleted from the PDL; and
- New guidelines or revisions to existing guidelines to evaluate the medical necessity of prescriptions submitted for prior authorization.

**DISCUSSION:**

During the June 21, 2019, meeting, the P&T Committee recommended the following revisions to the guidelines to determine medical necessity of Ophthalmics, Anti-Inflammatories:

- Specify that a request for a non-preferred agent requires a documented history of therapeutic failure, intolerance, or contraindication of the preferred Ophthalmic Anti-Inflammatories that are U.S. Food and Drug Administration-approved or medically accepted for the beneficiary’s diagnosis or indication; and
- Addition of prior authorization guidelines to determine medical necessity of intravitreal implants and injections.

The revisions to the guidelines to determine medical necessity of Ophthalmics, Anti-Inflammatories, as recommended by the P&T Committee, were subject to public review and comment and subsequently approved for implementation by the Department.

**PROCEDURE:**

The procedures for prescribers to request prior authorization of Ophthalmics, Anti-Inflammatories are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to Ophthalmics, Anti-Inflammatories) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs that require prior authorization.

**ATTACHMENTS:**

Prior Authorization of Pharmaceutical Services Handbook - Updated pages
RESOURCES:

Prior Authorization of Pharmaceutical Services Handbook – SECTION I
Pharmacy Prior Authorization General Requirements
http://www.dhs.pa.gov/provider/pharmacieservices/pharmacypriorauthorizationgeneralrequirements/index.htm

Prior Authorization of Pharmaceutical Services Handbook – SECTION II
Pharmacy Prior Authorization Guidelines
http://www.dhs.pa.gov/provider/pharmacieservices/drugsrequiringclinicalpriorauthorization/index.htm
I. Requirements for Prior Authorization of Ophthalmics, Anti-Inflammatories

A. Prescriptions That Require Prior Authorization

Prescriptions for Ophthalmics, Anti-Inflammatories that meet any of the following conditions must be prior authorized:

1. A non-preferred Ophthalmic, Anti-Inflammatory. See thePreferred Drug List (PDL) for the list of preferred Ophthalmics, Anti-Inflammatories at: https://papdl.com/preferred-drug-list.

2. An Ophthalmic, Anti-Inflammatory with a prescribed quantity that exceeds the quantity limit. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: http://www.dhs.pa.gov/provider/pharmacyservices/quantitylimitslist/index.htm.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Ophthalmic, Anti-Inflammatory, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. For a non-preferred Ophthalmic, Anti-Inflammatory, has a documented history of therapeutic failure, intolerance, or contraindication of the preferred Ophthalmics, Anti-Inflammatories that are U.S. Food and Drug Administration (FDA)-approved or medically accepted for the beneficiary's diagnosis or indication; AND

2. For an intravitreal implant or injection, all of the following:
   a. Is being prescribed the intravitreal implant or injection for an indication that is included in the FDA-approved package labeling OR a medically accepted indication,
   b. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature,
   c. Is prescribed a dose and duration of therapy that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature,
   d. Is prescribed the intravitreal implant or injection by an ophthalmologist;

   AND

3. If a prescription for an Ophthalmic, Anti-Inflammatory is in a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior

January 1, 2020
(Replacing November 16, 2009)
authorization will be approved

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Ophthalmic, Anti-Inflammatory. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.